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http://dx.doi.org/10.1016/j.ccell.2015.09.002SUMMARYGlioblastomas display hierarchies with self-renewing cancer stem-like cells (CSCs). RNA sequencing and
enhancermapping revealed regulatory programs unique toCSCs causing upregulation of the iron transporter
transferrin, the top differentially expressed gene compared with tissue-specific progenitors. Direct interroga-
tion of iron uptake demonstrated that CSCs potently extract iron from the microenvironment more effectively
than other tumor cells. Systematic interrogation of iron flux determined that CSCs preferentially require trans-
ferrin receptor and ferritin, two core iron regulators, to propagate and form tumors in vivo. Depleting ferritin
disrupted CSC mitotic progression, through the STAT3-FoxM1 regulatory axis, revealing an iron-regulated
CSC pathway. Iron is a unique, primordial metal fundamental for earliest life forms, on which CSCs have
an epigenetically programmed, targetable dependence.INTRODUCTION
Glioblastoma (GBM; World Health Organization [WHO] grade IV
glioma) is the most lethal and prevalent primary malignant brain
tumor in adults (Stupp et al., 2009). Even with the use of highly
aggressive therapies, recurrence is inevitable and prognosis is
dismal, with a median survival of 14–15 months (Stupp et al.,
2009). More effective therapeutic strategies are therefore urgent.
We and others have reported that GBMs contain cellular hierar-
chies with cells featuring stem-like properties at the apex, gov-
erned by the microenvironment (Eyler et al., 2011; Li et al.,
2009; Singh et al., 2004). The significance of cancer stem-like
cells (CSCs) is underscored by their resistance to conventionalSignificance
Glioblastoma is the most lethal primary brain tumor in part bec
cells (CSCs). We used RNA and ChIP sequencing to identify an
allows CSCs to preferentially scavenge iron more effectively th
microbial pathogens. Systematic interrogation of iron flux deter
core iron regulators, to propagate and form tumors in vivo. Disr
stream signaling of critical STAT3- and FoxM1-mediated pathw
programmed CSC metabolic node amenable for therapeutic t
Ctherapy (Bao et al., 2006a; Chen et al., 2012) and promotion of
tumor angiogenesis (Bao et al., 2006b). We and others have
also demonstrated that CSCs can be defined functionally by
their capacity to self-renew with an increased capacity to form
tumorspheres, express stem cell markers, differentiate into
multiple lineages, and phenocopy the original tumor in vivo
(Eyler et al., 2011; Flavahan et al., 2013; Lathia et al., 2010; Li
et al., 2009; Singh et al., 2004). CSCs endure and even thrive
in stressful tumor conditions, including hypoxia, oxidative stress,
inflammation, acidic stress, and low glucose (Flavahan et al.,
2013; Hjelmeland et al., 2011; Li et al., 2009; Venere et al.,
2014; Ye et al., 2012); all of these niches mediate effects in
part through iron metabolism (Huang et al., 2013; Peyssonnauxause of chemoresistant and radioresistant cancer stem-like
epigenetic program used almost exclusively in the liver that
an other tumor cells, resembling the activity of iron-starved
mined that CSCs require transferrin receptor and ferritin, two
upting ironmetabolism via ferritin targeting prevented down-
ays. Our findings uncover a hyper-activated, epigenetically
argeting.
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et al., 2007; Torti and Torti, 2013). This coalescence suggests
that exploiting aberrant iron regulation in tumors may uncover
a direct driver of CSC tumorigenicity and therapeutic resistance.
Iron has specific functions in a non-cancerous cell; it is
required for proteins or enzymes that regulate respiratory com-
plexes, DNA and heme synthesis, and mitosis and epigenetic
modifications, all of which are dysregulated in cancer (Lane
et al., 2014; Torti and Torti, 2013). However, most anticancer
therapies aimed at removing iron via chelation are not likely to
be cancer tissue specific, especially in the iron-dependent brain.
Therefore, targeting iron regulation within tumor-specific and/or
hyperactive pathways represents a potential approach to crip-
pling a key cancer dependency.
Regulated iron scavenging is fundamental and ubiquitous
throughout nature. We hypothesized that in GBM, CSCs scav-
enge iron by co-opting regulatory programs, typically reserved
for the liver and specialized regions in the brain such as the
choroid plexus (Leitner and Connor, 2012), to potentially secrete
and uptake transferrin (TF). To identify crucial downstream
iron-mediated CSC pathways, it is necessary to perform ‘‘iron-
tracing’’ experiments to measure iron uptake along with expres-
sion patterns of proteins needed for iron transport and storage.
Intracellular iron entry typically requires TF binding ferric iron
before complexing with TF receptor (TfR), followed by endocy-
tosis and eventual iron release into the cytoplasm (Torti and Torti,
2013). TfR is highly expressed inmany cancers, including breast,
lung, bladder, leukemia, lymphoma, and glioma, suggesting that
tumor cells exhibit increased iron demands (Daniels et al.,
2006a). Numerous oncology studies have attempted to harness
this intracellular delivery system. Whether targeting TfR directly
with antibodies, conjugating chemotherapeutics, such as doxo-
rubicin, cisplatin, and chlorambucil, to TF, and/or attaching ge-
netic vectors to TF, it is evident that TfR activity is involved in
tumor growth (Daniels et al., 2006a, 2006b). Yet it is unclear
how iron is driving tumor-specific pathways and/or if iron is pref-
erentially used within a heterogeneous tumor population, as may
be the case in GBM.
Because free iron acts as a catalyst for producing free radicals
via the Fenton reaction (Fe2+ + H2O2 / Fe
3+ + $OH + OH),
excess iron is stored in ferritin, a 24-subunit protein that can
store up to 4,500 iron atoms. The clinical importance of ferritin
in tumor growth is demonstrated in other cancers, contributingFigure 1. Upregulation of TF through Hepatocyte-Specific Epigenetic
(A) Heatmap of fold change of gene expression (FPKM from RNA sequencing) in C
CSCs comparedwith normal neural progenitor cells, while blue represents a decre
are IN528 CSCs versus hES cell-derived OPCs, glial progenitors (GPs) derived f
cursor cells (NPCs). OPC and GP data were generated from this study, while NP
(B) Top and bottom ten differentially expressed genes from cell types above (CS
(C) TF secretion was measured in CSCs and non-CSCs using 1 mg protein from
(D) PreSTIGE analysis (Corradin et al., 2014) was conducted on H3K4me1 ChIP s
determine enhancers predicted to target TF.
(E) University of California, Santa Cruz, Browser image depicting H3K4me1 peaks
in vitro (MGG) CSCs, black designates in vitro serum differentiated CSCs. Enhan
(F) Diagram of the experimental procedure for ex vivo imaging of TF uptake in br
(G) Reconstructions of representative fields showing TF (green) in CSCs (red) a
surface of the 3D reconstruction. ***p = 4.73 3 10166. The scale bar represents
(H) Radiolabeled iron (100 mM 55Fe bound to TF) uptake after 3 hr in CSCs comp
(I) Scavenge of iron (100 mM 55Fe) by CSCs and matched non-CSCs. ***p < 0.00
See also Figure S1 and Table S1.
Cto tumorigenesis by acting as an autocrine growth factor,
restoring tumor-dependent vessel growth, aswell as being asso-
ciated with invasion (Coffman et al., 2009; Holtkamp et al., 2005;
Kikyo et al., 1994). Ferritin targeting also sensitizes glioma cells
to chemotherapy (Liu et al., 2011). We hypothesize that altering
iron availability in CSCs ablates drivers of the stem cell pheno-
type and targeting ferritin represents a point of fragility of iron
addicted CSCs.
RESULTS
CSCs Use a Hepatocyte- and Tumor-Specific Epigenetic
Program to Upregulate and Secrete TF
To discover therapeutically viable gene and pathway targets in
CSCs, we performed next-generation RNA sequencing on a vali-
dated GBM CSC model as well as normal brain progenitor cell
populations (Figure 1A). We sought to discover targets highly ex-
pressed in the CSCs but not in normal neuronal and glial progen-
itors, to avoid targets likely to introduce CNS toxicity. TF was the
top differentially expressed gene compared with oligodendro-
cyte progenitor cells, the most abundant CNS progenitor cell in
the adult brain, as well as in the top six differentially regulated
genes compared with both astroglial and neural progenitor cells
(Figure 1B). We validated that TF protein was highly upregulated
in GBM compared with normal brain (Figures S1A and S1B), with
expression present in mitotic cells and perivascular niches in
GBM (Figures S1C and S1D). Although not statistically signifi-
cant, likely because of limited sample size, there was a trend to-
ward worse survival in GBM patients with high TF expression
(Figure S1E). In the normal brain, only the choroid plexus se-
cretes TF (Leitner and Connor, 2012), potentially because of
alternative splicing variants of TF in TF-producing cells, such ol-
igodendrocytes (de Arriba Zerpa et al., 2000). However, we
determined that CSCs (CD133+ cells) secrete high levels of TF,
whereas TF secretion was barely detectable in non-CSCs
(CD133 cells) (Figure 1C). To understand how TF was being
regulated in CSCs, we performed epigenomic profiling of the
same CSC model as in Figure 1A using chromatin immunopre-
cipitation (ChIP) sequencing and compared this profile to pub-
lished data sets. We focused our analysis on putative enhancer
elements, marked by H3K4 mono-methylation (H3K4me1). En-
hancers are tissue-specific regulatory elements, and gainedProgram and Increased Iron Uptake via TF in CSCs
SCs versus normal neural progenitors. Red represents increased expression in
ase in expression in CSCs comparedwith normal controls. Samples compared
rom acute dissociated epilepsy resection, and hES cell-derived neuronal pre-
C data are from Sauvageau et al. (2013).
C FPKM/OPC FPKM).
each xenograft specimen added to a TF ELISA (Abcam). ***p < 0.001.
equencing data from CSCs and 13 Encyclopedia of DNA Elements cell lines to
at the TF locus. Red background designates acutely dissociated (p0) CSCs or
cers predicted by PreSTIGE to target TF in p0 CSCs.
ain slices.
nd non-CSCs (blue) and quantification of fluorescent-Tf as measured on the
10 mm.
ared with non-CSCs. **p < 0.01; ***p < 0.001.
1. The error bars represent ±SEM.
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enhancers in cancer have been shown to mark cancer depen-
dency genes (Akhtar-Zaidi et al., 2012). We used the algorithm
PreSTIGE (Corradin et al., 2014) to call enhancers predicted to
regulate TF in CSCs, as well as in other somatic and neoplastic
cell types. Only CSCs and HepG2, a well-differentiated liver car-
cinoma cell line often used to study hepatocyte function, had en-
hancers predicted to target TF (Figure 1D). Both CSCs and
HepG2 cells had multiple, overlapping enhancers targeting TF,
some of which were lost upon CSC differentiation (Figure 1E).
Together, these data suggest that CSCs gain a hepatocyte-spe-
cific epigenetic regulatory program that allows them to upregu-
late TF expression.
Iron Uptake Is Enhanced in CSCs
To demonstrate preferential iron scavenging ability in GBM
CSCs, we developed an ex vivo transplant model in which
non-neoplastic brain slice cultures were implanted with fluores-
cently labeled CSCs and non-CSCs followed by TF loading and
subsequent imaging (Figure 1F). We isolated matched CSC and
non-CSC populations on the basis of sorting for CD133 (Table
S1), a protein epitope we have repeatedly validated as a marker
of CSC self-renewal (Figure S1F) and tumor formation.
Although the use of this marker is controversial because it
has not been universally informative across all tumors, and no
perfect CSC marker has been identified, our lab has repeatedly
shown that CD133 informs a fraction of GBM cells that enrich
for a functional CSC hierarchy of tumorigenic and non-tumori-
genic cells (Figure S1F) (Bao et al., 2006a; Eyler et al., 2011;
Flavahan et al., 2013; Hjelmeland et al., 2011; Lathia et al.,
2010; Li et al., 2009; Venere et al., 2014; Yan et al., 2014).
Furthermore, CSCs from our models express putative neural
stem cell markers (i.e., Sox2, Olig2, A2B5, Tuj1, and Oct4),
consistent with the xenografts used in the current studies
(Yan et al., 2014).
Multiphoton imaging of our ex vivo transplant model and 3D
reconstruction of TF co-localization with the tumor cell surface
demonstrated that the amount of bound TF was more than 20-
fold higher in CSCs compared with non-CSCs under the same
conditions (Figure 1G). As a complementary approach to verify
this difference, we quantified the uptake of radiolabeled iron
(55Fe). CSCs and non-CSCs grown in identical culture conditions
were treated with TF-conjugated iron for 3 hr, resulting in up to 3-
fold greater uptake in CSCs (Figure 1H). We hypothesized that if
CSCs actively produce and secrete TF, unbound iron uptake
should be elevated even in the absence of experimentally com-
plexed iron with TF. This route of iron uptake was at least 2-fold
higher in CSCs compared with uptake in non-CSCs (Figure 1I),
even exceeding the uptake of activated human macrophages
(data not shown), which commonly serve as a positive control
(Kuhn et al., 1999).
TfR Expression Is Indicative of Increased
Tumorigenicity
We compared ChIP sequencing of H3K27 acetylation at the TfR
loci (encoded by TFRC) in normal brain, GBM, CSCs, and non-
CSCs (Figure S2A) as well immunohistochemically in non-
neoplastic brains and in gliomas (WHO grades II, III, and IV) (Fig-
ure S2B). Consistent with in silico analysis (Figures 2A and 2B),
neuropathological scoring of TfR immunohistochemical (IHC) in-444 Cancer Cell 28, 441–455, October 12, 2015 ª2015 Elsevier Inc.tensity from a tumor microarray demonstrated a grade depen-
dence with nearly 2-fold higher TfR in grade IV gliomas
compared with lower grade tumors (Figure 2C). The Repository
for Molecular Brain Neoplasia Database (REMBRANDT) and
The Cancer Genome Atlas (TCGA) data sets along with our
IHC analysis each revealed a negative correlation between TfR
and survival (Figures 2D–2F and S2C).
Similar to patient GBM tissue, TfR was expressed in multiple
GBM xenografts and co-localized with Sox2, a transcription fac-
tor recognized as a putative CSC marker (Figure 2G) and also
increased in CSCs compared with non-CSCs (Figure 2H). Recy-
cling of the TfR complex occurs following the release of iron from
the endosome. We used a biotinylation assay to segregate and
measure cell surface (membrane) and cytosolic protein fractions
of TfR (Figure 2I). Cells were grown to equal confluency in
identical media conditions to mitigate any potential differences
in receptor expression that could be attributed to cell density.
ERK1/2 served as a separation control, representing a molecule
not normally expressed on the membrane surface. Although
cytosolic TfR was indistinguishable between cell types, the
membrane fraction was noticeably elevated in CSCs, suggesting
that the surface level expression accounts for the overall in-
crease of TfR in CSCs, likely because of increased recycling or
upregulation of TfR (Figure 2I).
TfR comprised an average of 55% of the total tumor popu-
lation of freshly dissociated patient-derived xenografts as
analyzed by flow cytometry (Figure S3A). Indeed, TfR expres-
sion is not restricted to CSCs, nor is it likely a CSC marker, yet
TfR/Sox2 co-localization prompted us to investigate if TfR was
essential for CSC maintenance, including the formation of tu-
morspheres from a single cell in vitro. Bulk GBM cells positive
or negative for TfR were plated by limiting dilution and evalu-
ated for tumorsphere formation 10 days later. TfR-positive
cells consistently formed tumorspheres at a greater frequency
than TfR-negative cells (Figure 3A). Likewise, plating TfR-pos-
itive cells increased the percentage of wells containing tumor-
spheres by 25-fold (plating 1 cell/well) and 10-fold (plating 10
cells/well) (Figure 3B). In vivo xenografting with limiting dilution
on the basis of high or low TfR expression showed that mice
bearing TfR-high cells developed tumors with a shorter latency
and increased tumor incidence with decreased survival com-
pared with mice bearing TfR-low cells (Figures 3C–3F, S3B,
and S3C). These results demonstrate the importance of iron
acquisition for CSC self-renewal and tumor initiation. This
was further demonstrated by performing limited dilution as-
says in the context of CSCs that were either positive or nega-
tive for TfR, which revealed that TfR expression increased the
stem cell frequency of CSCs by nearly 10-fold (Figures S3D
and S3E).
Ferritin Is a Negative GBM Prognostic Factor and Is
Increased in CSCs
Once shuttled out of the endosome, iron is either used immedi-
ately or stored in ferritin, which is made up of two subunits with
non-overlapping functions: heavy chain (H-ferritin [FTH1]) and
light chain (L-ferritin [FTL]). To circumvent the challenge of de-
tecting free iron, we used FTH1 and FTL as indicators of iron
flux into CSCs. Intracellular free iron leads to ferritin mRNA trans-
lation, resulting in increased iron storage. Treating CSCs with
Figure 2. Elevated TfR Expression in GBM Indicates Poor Prognosis
(A and B) Analysis of brain tumor data sets from Oncomine for the mRNA level of TFRC in GBM compared with non-neoplastic brain (A, Sun data set) and in high-
grade glioma compared with lower grade glioma (B, Phillips data set).
(C) IHC scores of TfR in different grades of glioma in the Horbinski data set.
(D and E) Analysis of correlation between TFRC mRNA expression and glioma patient survival (D, REMBRANDT data set; E, TCGA data set). High expression
represents 2-fold elevation versus intermediate expression with log rank analysis. Low expression represents <2-fold reduction versus intermediate expression
with log rank analysis.
(F) Analysis of TfR protein expression score with patient survival; Horbinski data set (WHO grades II–IV).
(G) Immunofluorescence (IF) of TfR (red), Sox2 (green), and DAPI (blue) in GBM xenograft tissue. The scale bar represents 50 mm.
(H) Western blot of TfR and b-actin in CSCs and non-CSCs from three different GBM xenografts.
(I) Membrane and cytosol fractions of TfR were determined in CSCs and non-CSCs. The error bars represent ±SEM.
See also Figure S2.iron for 3 hr increased FTH1 and FTL protein levels, which
continued to increase for 24 hr (Figure 4A). These data suggest
that CSCs scavenge iron to the extent that storage machinery
needs to be increased to buffer any potential negative conse-Cquences of free iron and to regulate proper intracellular iron
distribution.
On the basis of in silico analysis of published gene expres-
sion databases, FTH1 and FTL are expressed higher in GBMancer Cell 28, 441–455, October 12, 2015 ª2015 Elsevier Inc. 445
Figure 3. TfR Drives Sphere Formation
In Vitro and Tumor Formation In Vivo
(A) In vitro limiting dilution assays plating
decreasing numbers of fluorescence-activated cell
sorted TfR+ or TfR tumor cells from freshly
dissociated GBM xenografts calculated with
extreme limiting dilution assay (ELDA) analysis
(top). Stem cell frequencies from TfR+ and TfR
cells were calculated as the ratio 1/x, where 1 =
stem cell and x = all cells (bottom).
(B) Percentage of wells that formed tumorspheres
from either TfR+ or TfR GBM cells based on
plating 1 cell/well (left) or 10 cells/well (right). The
error bars represent ±SEM.
(C and D) Survival curves of mice orthotopically
implanted with TfR-high or TfR-low expressing
GBM cells at dilutions of 1,000 cells (C) or 100 cells
(D); n = 5 for all groups.
(E and F) Median survival (E, in days post-injection)
and tumor incidence (F, in days) in mice bearing
GBM cells.
See also Figure S3.compared with non-neoplastic brain, with a strong correlation
with FTH1 and FTL gene expression patterns (Figure 4B). In
a separate patient cohort, we performed IHC scoring for
FTH1 and FTL expression, which increased with glioma grade
(Figure 4C), correlated with worse survival (Figure 4D), and
was further validated by comparing survival curves of GBM
patients from the TCGA data set (Figure 4E). Ferritin expres-
sion increased with tumor grade (Figure 4F) yet appeared
confined to subsets of cells and tumor niches, suggesting
that not every tumor cell is equally iron dependent. In GBM-
derived xenografts, ferritin co-localized with Sox2 (Figure 4G),
prompting us to analyze ferritin protein expression in CSCs
and non-CSCs. In all GBM specimens, FTH1 and FTL pro-
teins were elevated in CSCs compared with matched non-
CSCs cultured identically (Figure 4H). These data indicate
that iron storage is elevated in CSCs, suggesting greater
iron dependence compared with non-CSCs and the non-
neoplastic brain.446 Cancer Cell 28, 441–455, October 12, 2015 ª2015 Elsevier Inc.Targeting Ferritin Expression
Decreases CSC Growth In Vitro and
In Vivo
To determine if ferritin maintains CSC
tumorigenicity, short hairpin RNA interfer-
ence (shRNA) was transduced into CSCs
to ablate ferritin activity. Validated con-
structs (Figures S4A–S4D) with unique
sequences at non-overlapping regions
exhibiting the best knockdown were cho-
sen (referred to hereafter as FTH1 shRNA
or FTL shRNA), along with a control, non-
targeting shRNA sequence that does not
target a mammalian sequence (referred
to as NT shRNA). FTH1 and FTL shRNA
depleted ferritin mRNA and protein levels
in CSCs across multiple specimens (Fig-
ures 5A and 5B). As hypothesized, ferritin
knockdown decreased TfR expression,likely because of released intracellular free iron causing a
negative feedback loop. Both ferritin chains are necessary for
proper storage function, yet it is unknown if targeting either
subunit separately affects the overall tumorigenicity of CSCs.
We hypothesized that preventing the ability to properly store
and control iron would halt CSC proliferation, severely affecting
their growth. This became evident in examining tumorsphere
formation, which was robustly diminished by ferritin knockdown
(Figures 5C and 5D). FTH1 or FTL knockdown affected
cellular fitness in CSCs by stunting growth (Figure 5E). Prolifera-
tion, indicated by thymidine incorporation, decreased by more
than 7-fold in CSCs transduced with either FTH1 or FTL shRNA
(Figure 5F). Elevated ferritin expression in CSCs suggests
increased iron demand and/or dependence; therefore, we
expected that targeting ferritin would be more detrimental
to CSCs compared with non-CSCs or non-neoplastic brain
cells. In this separate study, growth of non-neoplastic adult brain
cells was least affected by ferritin knockdown (Figure S4E),
Figure 4. Ferritin Is Preferentially Expressed in CSCs
(A) Western blot of FTH1 and FTL following treatment with 100 mM Fe.
(B) In silico analysis of brain tumor data sets from Oncomine showing FTH1 and FTL expression in GBM compared with normal brain tissue. Middle box line
represents median, top box line represents upper quartile, bottom box line represents lower quartile, top error bar represents 90th percentile, and bottom error
bar represents 10th percentile. ***p < 0.001.
(C) Quantification of FTH1 and FTL IHC intensity with glioma grade. The error bars represent ±SEM.
(D) Correlation between overall survival of glioma patients and FTH1 and FTL IHC score of their tumors from the Horbinski data set (WHO grades II–IV).
(E) Correlations between FTH1 or FTL expression and patient survival in the TCGA data set.
(F) Ferritin IHC of control brain, low-grade, and high-grade glioma tissue. The scale bar represents 50 mm.
(G) IF labeling of GBM xenografts with FTH1 (top, red) or FTL (bottom, red), Sox2 (green), and DAPI (blue). The scale bar represents 50 mm.
(H) Western blot of FTH1, FTL, and b-actin in CSCs and non-CSCs from six different GBM xenografts.
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Figure 5. Targeting Ferritin Decreases CSC Growth In Vitro and Tumor Formation In Vivo
(A and B) Quantitative RT-PCR of FTH1 and FTL mRNA (A) and immunoblot of proteins (B) in CSCs following transduction with NT, FTH1, or FTL shRNA.
(C) CSC-derived tumorsphere formation following ferritin knockdown. The scale bar represents 200 mm.
(D) In vitro limiting dilution assays of CSCs transduced with NT, FTH1, or FTL shRNA calculated with ELDA analysis.
(E) ATP-dependent growth in CSCs after ferritin knockdown. *p < 0.05. ***p < 0.001.
(F) CSC proliferation following ferritin knockdown, measured by 3H-thymidine incorporation. ***p < 0.001.
(G) In vivo imagining 2 weeks post-orthotopic injection of CSCs expressing luciferase, transduced with NT, FTH1, or FTL shRNA.
(H) Kaplan-Meier curves indicating survival of mice bearing intracranial injections of 10,000 CSCs with ferritin knockdown. The error bars represent ±SEM.
See also Figure S4.
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suggesting a potentially high therapeutic index for ferritin target-
ing in GBM.
Extending these studies to in vivo orthotopic models, 10,000
viable, luciferase-expressing CSCs acutely transduced with
NT, FTH1, or FTL shRNA were intracranially implanted into
mice followed by in vivo monitoring. Although mice with NT
shRNACSCs began to develop tumor symptomswithin 2weeks,
there were no signs of tumors in mice with FTH1 or FTL shRNA
CSCs at this time point (Figure 5G). Validation with CSCs derived
from an additional human specimen produced nearly identical
results (data not shown), and tumor formation was virtually ab-
sent in mice that received CSCs from either specimen with
ferritin knockdown (Figure 5H). These results demonstrate that
iron storage is critical for tumor formation. Without ferritin, an
abundance of uncontrolled iron likely blocks the necessary steps
necessary for CSCs to propagate and create an environment en-
riched for forming tumors.
Molecular Mediators of Ferritin
The loss of proper iron storage severely decreases CSC survival
and tumor-forming capabilities, so we set out to identify molec-
ular nodes downstream of ferritin that are vital to CSC biology,
that are amenable to therapeutic targeting, andwhose disruption
may explain our observed results. Because loss of either FTH1 or
FTL is vital for CSC biology, we interrogated the TCGA database
to confirm relative homologous gene correlations and ferritin
expression across GBM subtypes (Figures 6A and 6B). Next,
CSCs isolated from five different GBM patients were transduced
with NT, FTH1, or FTL shRNA, with verification of ferritin knock-
down followed by analysis with Affymetrix HuGene 2.1 chips for
whole-transcriptome profiling. Of the total 40,716 RefSeq tran-
scripts profiled, genes were analyzed by computing the robust
multi-array average across all samples, followed by selecting
only genes that were increased or decreased by at least 2-fold
following FTH1 and FTL knockdown across all five specimens
(Table S2). Our initial studies focused on the 116 downregulated
genes (Figure 6C). Classifying these genes on the basis of
ontology, we discovered the largest subset of genes were pri-
marily involved with cell cycle and mitosis (84 of 116 [71.8%]),
followed by DNA damage response (29 of 116 [24.8%]) and
Rho GTP signaling (7 of 117 [5.98%]), keeping in mind that the
roles of some genes overlap across multiple pathways (Fig-
ure 6C). Consistent with these data were gene set enrichment
plots verifying that loss FTH1 and FTL impairs expression of
cell cycle-associated genes (Figure 6D). To confirm that ferritin
inhibition dysregulates theCSC cell cycle, we performed flow cy-
tometry-based cell cycle profiling; FTH1 or FTL shRNA reduced
time spent in the S phase (Figures 6E, S5A, and S5B). FTH1
knockdown increased time spent in G0/G1, while FTL knock-
down caused G2/M arrest. Collectively, these results suggest
that ferritin function critically regulates cell cycle progression
in CSCs.
STAT3 and FoxM1 Regulation Is Affected by Ferritin
Knockdown
We analyzed our data set for the genes most correlated with
ferritin expression and discovered that signal transducer and
activator of transcription 3 (STAT3) had the highest correlation
value (Figure 7A), providing a potential clue for downstreamCpathways of ferritin signaling. Ingenuity’s upstream regulator
analysis identified transcriptional regulators that most likely
explain the observed gene expression data changes within our
data set. From this analysis, the STAT3-regulated transcription
factor FoxM1 was found to have the highest activation Z score
in both FTH1 shRNA and FTL shRNA samples (Figure 7B).
FoxM1 is a transcription factor known to play a pivotal role in
cell cycle signaling in many cancers, including being overex-
pressed in GBM (Hodgson et al., 2009; Liu et al., 2006; Zhang
et al., 2011), and has recently been identified to interact with
b-catenin (Zhang et al., 2011) and themitotic kinaseMELK (Joshi
et al., 2013) in CSCs, regulating their self-renewal and prolifera-
tion. On the basis of our gene expression analysis, FOXM1 was
decreased by twofold in CSCs depleted of FTH1 or FTL (Fig-
ure S6A). Ferritin knockdown in CSCs reduced FoxM1, phos-
phorylated, and, to a lesser extent, total STAT3 protein levels
aswell as FoxM1promoter activity (Figures 7C and 7D), suggest-
ing a ferritin-STAT3-FoxM1 feedback loop. Further confirming
the importance of ferritin for FoxM1 function, mRNA of FoxM1
downstream targets was all decreased following ferritin knock-
down (Figure 7E), consistent with reduced FoxM1 occupancy
as measured by ChIP (Figure 7F). FoxM1 rescue experiments
were performed in which CSCs were first infected with NT con-
trol sequence, FTH1, or FTL shRNA, followed by transient trans-
fection with either a FoxM1 overexpression construct or empty
vector control. After 48 hr, FoxM1 overexpression restored and
even improved CSC growth (Figures 7G and S6B). These results
support FoxM1 as an essential downstream mediator of ferritin
in CSCs.
DISCUSSION
Absolutely essential for life, iron regulation is prominently ex-
pressed in the CSC transcriptome, with iron mediating interplay
with the tumor microenvironment, epigenetic modifications, ge-
netic mutations, and altered metabolism, processes increasingly
connected in driving CSC maintenance and therapeutic resis-
tance. Given the unique ability to donate and accept electrons,
iron homeostasis must always be maintained; yet in GBM, iron
flux is asymmetrical, with CSCs emulating a bacteria-sidero-
phore-like system in which TF is epigenetically regulated and
secreted to potentially ensure that CSCs are able to scavenge
sufficient iron. This program results in a cascade of events in
which TfR recycling and ferritin translation increase. Although
iron regulators have long been recognized as involved in cancer
biology, specifically how and why subsets of cancer cells use
iron to sustain tumor growth has been unclear. We now demon-
strate a targetable molecular fingerprint of iron in CSCs involving
a series of tumor-specific feedback loops that are likely amplified
and/or dysfunctional depending on cues derived from stem cell
niches.
TfR and ferritin are intricately regulated by iron, but expression
may be induced by microenvironmental influences, including
those we and others previously identified as promoters of the
CSC phenotype, such as nitric oxide (Eyler et al., 2011; Recalcati
et al., 1998) and the cytokines NF-kB (Hjelmeland et al., 2010;
Kwak et al., 1995; Pham et al., 2004) and TGF-b (Koorts et al.,
2011; Schober and Fuchs, 2011; Shinojima et al., 2013). In
turn, ferritin can act as a proinflammatory cytokine, potentiallyancer Cell 28, 441–455, October 12, 2015 ª2015 Elsevier Inc. 449
Figure 6. Gene Expression Profiling Reveals Ferritin Dependence for Cell-Cycle Progression
(A) Genome-wide analysis of TCGAGBMdata set that demonstrates genes (points on graph) displaying correlation coefficients with FTH1 (x axis) and correlation
coefficients with FTL (y axis).
(B) FTH1 and FTL expression in TCGA GBM data set on the basis of subtype.
(C) Affymetrix HuGene 2.1 microarray analysis of all genes decreasedR2-fold from five different GBM specimens following ferritin shRNA compared with NT
shRNAs.
(legend continued on next page)
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independent of iron status (Ruddell et al., 2009). Likewise, the
angiogenic and hypoxic CSC niches also likely rely on a bi-direc-
tional relationship with iron, given that ferritin controls angiogen-
esis by binding to and inhibiting the anti-angiogenic properties of
cleaved high-molecular weight kininogen (Coffman et al., 2009).
Activation of HIF prolyl hydroxylases requires an iron chaperone,
poly (rC) binding protein 1 (PCBP1), which delivers iron to ferritin
(Nandal et al., 2011). Currently under investigation is whether
these interactions exist in GBM, predominantly affecting CSCs,
and how ferritin preferentially directs iron toward being used in
CSC-specific pathways, providing a new strategy for designing
GBM therapies.
TF is a secreted protein, making it a potentially difficult part of
the iron pathway to design therapeutic agents against, and TfR is
important even for the normal brain; therefore, we chose to focus
on understanding the downstream effects of targeting ferritin,
consisting of a set of proteins with cell-specific distribution pat-
terns (Connor et al., 1994). We identified STAT3 phosphorylation
and FoxM1 signaling as the most notable pathways affected by
ferritin depletion. Out of all the genes in our microarray, STAT3
correlated the most with ferritin expression. STAT3 is a critical
CSC signaling node (Cao et al., 2010; Kim et al., 2013) upstream
of FoxM1 (Mencalha et al., 2012) that also leads to promoter
binding ofMyc (Zhao et al., 2014), an oncogenic ferritin repressor
(Wu et al., 1999), and Sox2 (Zhao et al., 2014), a stem core cell
transcription factor that we found co-localized in CSCs express-
ing ferritin. The bi-directional FoxM1-STAT3 signaling axis has
recently been fortified in GBM, whereas FoxM1 is also required
for the STAT3 activation required to promote CSC self-renewal
and tumorigenicity (Gong et al., 2015). We demonstrate that at
a minimum, this pathway is sensitive to changes in iron homeo-
stasis. We postulate another scenario: STAT3 and FoxM1
signaling are iron dependent and/or require direct ferritin bind-
ing. Excessive free iron, not contained by ferritin (which we hy-
pothesize to occur in our model using ferritin shRNAs), induces
the formation of free radicals and reactive oxygen species, trig-
gering the activation of antioxidant-responsive elements (AREs)
located in FTH1 and FTL (Iwasaki et al., 2007; Wasserman and
Fahl, 1997). ARE binding represses ferritin function; however,
this is counteracted by the protein inhibitor of activated STAT3
(PIAS3) (Iwasaki et al., 2007). PIAS3 stabilization of ferritin may
represent part of the feedback loop in which STAT3 and down-
stream signaling targets such as FoxM1 hinge on ferritin activity.
Further supporting an iron-STAT3 regulatory axis is STAT3-
mediated induction of hepcidin, an enzyme produced in the liver
that prevents iron export (Wrighting and Andrews, 2006). Similar
to the effects of CSCs upregulating TfR, hepcidin activity results
in increased intracellular iron and ferritin translation. We hypoth-
esize that the increased ferritin in CSCs directly interacts with
STAT3 and/or potentiates STAT3 phosphorylation. Therefore,
without ferritin intact, this autocrine system is inhibited andmight
explain the inability of CSCs to develop tumors when FTH1 and
FTL were depleted. CSC dependence on ample iron trafficking
through TfR and ferritin was further evident when we segregated(D) Gene set enrichment analysis using the C2 canonical pathways Broad MsigD
FTH1 (left) or FTL (right) knockdown.
(E) Cell-cycle analysis of two GBM specimens following transduction with NT, FT
See also Figure S5 and Table S2.
Cacutely dissociatedGBMcells solely off of TfR expression, which
was enough to dictate tumor formation in vivo, occurring in the
absence of mutations or growth factor stimuli.
CSCs represent a small tumor cell subset, ranging from 0.1%
to 10% of the overall GBM cytoarchitecture (Bao et al., 2006a;
Yan et al., 2014). On the basis of our microarray data, only
1% of all genes in CSCs were decreased more than 2-fold
(our threshold for significance) by ferritin knockdown, yet the
functional consequences of losing these genes were significant.
This suggests that the biological insult of altering iron flux
through ferritin inhibition in CSCs is not a passive or random
event. This needs to be taken into account when designing effec-
tive treatment strategies. Current iron-based treatment strate-
gies are focused on iron chelation therapy, which removes
intracellular iron from any cell, carrying significant side effects.
Given that CSCs take up more iron than non-CSCs, thereby
providing a buffering capacity should there be a sudden loss of
iron, it is unlikely that iron chelation will be effective in treating
GBM or other CSC-driven tumors. Alternatively, we demon-
strated that targeting the ability of a cell to control iron by inhibit-
ing proper iron storage was the most detrimental to cells with the
highest iron demands. Our studies demonstrate the importance
of looking beyond considerations of iron as only a ubiquitous, un-
targetable metal and instead indicate the feasibility of dis-
rupting iron flux in CSCs, a cell type difficult to penetrate with
current therapies. Moving forward, we envision broadening this
understanding while integrating nanotechnology platforms and
small-molecule inhibitors against regulators of iron handling in
designing effective therapies for GBM.
EXPERIMENTAL PROCEDURES
For details of standard lab techniques see Supplemental Experimental
Procedures.
Human GBM Specimens and Derivative CSCs
GBM tissues were obtained from excess surgical materials from patients with
informed consent at Duke University, Mayo Clinic, Cleveland Clinic, the Uni-
versity of Kentucky, and Odense University Hospital after review from a neuro-
pathologist in accordance with an approved protocol by the institutional
review board (United States) and the Committee on Health Research Ethics
(Denmark). Functionally validated GBM CSCs and/or non-CSCs were derived
immediately after dissociation of xenograft (transiently) passaged in immuno-
compromised mice using prospective sorting and in some cases transiently
cultured in vitro. For all experiments in which CSCs and non-CSCs were
directly compared, Geltrex (Invitrogen) was used to attach cells to tissue-cul-
ture plates and a medium consisting of CSC medium (Neurobasal Medium
[NBM; Invitrogen] + B27 [without vitamin A; Invitrogen] + 20 ng/ml epidermal
growth factor/fibroblast growth factor) with 1% fetal bovine serum was used
for long-term studies (beyond 24 hr), whereas in short-term experiments
(less than 6 h), a null medium consisting of only NBMwas used. For further de-
tails, see Supplemental Experimental Procedures.
Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor
Cells and Isolation and Culture of Primary Normal Glial Progenitors
Human oligodendrocyte progenitor cells (OPCs) were differentiated from
the human embryonic stem (hES) cell line H7 over a 154-day protocol, asB database on gene expression data compared non-targeting control against
H1, or FTL shRNA.
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Figure 7. FoxM1 Signaling Requires Intact Ferritin
(A) Correlation of STAT3 with total ferritin following ferritin knockdown. Colors represent individual xenograft specimens.
(B) Ingenuity upstream analysis of pathways downregulated by ferritin shRNA-derived gene expression data.
(C) Immunoblot of FoxM1, pSTAT3, and total STAT3 following ferritin knockdown in CSCs.
(D) Ferritin knockdown effect on FoxM1 promoter activity in 08-387 CSCs, measured with a luciferase reporter construct. ***p < 0.001.
(E) Relative mRNA levels of FoxM1 downstream targets derived from gene expression data (averages taken from specimens 4121, 3832, 3691, 08-387, and
GBM10). *p < 0.05; **p < 0.01; ***p < 0.001.
(F) ChIP PCR of FoxM1 targets performed on 08-387 CSCs transduced with NT, FTH1, or FTL shRNA.
(G) Transient FoxM1 overexpression in 08-387 CSCs 48 hr following ferritin knockdown. *p < 0.05; ***p < 0.001. The error bars represent ±SEM.
See also Figure S6.
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previously demonstrated (Wang et al., 2013). Normal, non-neoplastic cells
were derived from patient tissue specimens of neurosurgical resection in
accordance with a Cleveland Clinic Institutional Review Board-approved pro-
tocol. Cells that grew out were sorted for A2B5 and characterized by marker
staining to be proliferating cells of the glial lineage. For details, see Supple-
mental Experimental Procedures.
RNA Sequencing
RNA was isolated using standard methods. Library was prepared with the
Illumina TruSeq RNA Sample Preparation Kit and sequenced on the Illumina
HiSeq 2500 platform at the Case Western Reserve University Genomics
Core Facility. Reads were aligned to hg19 using Tophat and analyzed with Cuf-
flinks. For details, see Supplemental Experimental Procedures.
ChIP Sequencing
H3K4me1ChIP was performed from 5 3 106 crosslinked p0-CSCs, and
sequencing libraries were prepared as previously described (Corradin et al.,
2014). For details, including predicting gene targets of enhancers with
PreSTIGE, see Supplemental Experimental Procedures.
Tissue Microarray Immunohistochemistry and Survival Analysis
The glioma tissue microarray (TMA) and semiquantification of IHC data were
performed as described previously (Gilbert et al., 2014). Briefly, three 2-mm-
diameter cores per deidentified tumor were obtained and semiquantified on
a relative scale from 0–3 (0 = negative, 3 = strongest). Results from all three
cores were averaged together to produce a final score for a tumor. For details,
see Supplemental Experimental Procedures.
Cell-Cycle Analysis
Cells were fixed, stained with PI staining buffer (10 mg/ml propidium iodide,
10 mg/ml RNase A, and 0.5% Triton X-100 in PBS) for 30 min at 37C, spun
down, and resuspended in PBS. Samples were acquired with FACScan (BD
Biosciences) and analyzed using Modfit (Verity) and FlowJo (Tree Star)
software.
In Vitro Limiting Dilution Assay and Tumorsphere Formation
Propidium iodide-negative cells (n R 6) were flow-sorted with decreasing
numbers of cells per well (1, 5, 10, 20, 50, and 100) plated in 96-well plates.
Extreme limiting dilution analysis was performed using software available at
http://bioinf.wehi.edu.au/software/elda/. Tumorsphere formation assays
were also performed similarly to those in our previous reports (Flavahan
et al., 2013), with 1 cell per well and 10 cells per well plated in 96-well
plates, and the percentage of wells with tumorspheres was measured after
10 days.
Vectors and Lentiviral Constructs
Overexpression vectors (pcDNA 3.1 negative control and FoxM1-WT; a kind
gift from Dr. Ichiro Nakano, The Ohio State University) and FoxM1 promoter
pGL3 luciferase vectors (a kind gift from Dr. Suyun Huang, University of Texas
MD Anderson Cancer Center) were transfected using Fugene HD (Promega)
according to the manufacturer’s instructions. Luciferase-based FoxM1 pro-
moter activity was normalized to b-gal and renilla transfection levels. See
Supplemental Experimental Procedures for lentiviral production details, clone
sequences for FTH1 and FTL shRNA, and FoxM1 overexpression.
In Vivo Tumor Initiation Assay
All animal procedures were performed in accordance with Cleveland Clinic
Institutional Animal Care and Use Committee-approved protocols. For in vivo
limiting dilution studies, acutely dissociated GBM xenografts were sorted as
TfR high (top 20%) and TfR low (bottom 20%) and recovered for 1 hr in a
37C incubator. Three dilutions (10,000, 1,000, or 100 cells; n = 5 mice per
group) were intracranially injected into mice 4–6 weeks of age. Brains were
removed at the onset of neurological signs. For ferritin shRNA studies, lucif-
erase-labeled CSCs were transduced with lentiviral vectors expressing NT,
FTH1, or FTL shRNA. At 2 days post-transduction, 10,000 viable cells were
intracranially injected into mice as previously described (Flavahan et al.,
2013; Yan et al., 2014). A Xenogen IVIS (PerkinElmer) was used for in vivo
imaging.CRetrospective Analysis of TFRC, FTH1, FTL, and FOXM1 Gene
Expression in Human Gliomas
Correlations between glioma grade, patient survival, and gene expression
were determined through analysis of TCGA, Sun, Nutt, Freije, and Phillips brain
data sets, which are available through Oncomine (Compendia Biosciences;
http://www.oncomine.org). For details, see Supplemental Experimental
Procedures.
Statistical Analysis
See Supplemental Experimental Procedures for all statistical analysis
performed.
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